Triple Negative Breast Neoplasms
"Triple Negative Breast Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.
| Descriptor ID |
D064726
|
| MeSH Number(s) |
C04.588.180.788 C17.800.090.500.788
|
| Concept/Terms |
Triple Negative Breast Neoplasms- Triple Negative Breast Neoplasms
- ER-Negative PR-Negative HER2-Negative Breast Neoplasms
- ER Negative PR Negative HER2 Negative Breast Neoplasms
- Triple-Negative Breast Cancer
- Breast Cancer, Triple-Negative
- Breast Cancers, Triple-Negative
- Triple-Negative Breast Cancers
- Triple-Negative Breast Neoplasm
- Breast Neoplasm, Triple-Negative
- Breast Neoplasms, Triple-Negative
- Triple Negative Breast Neoplasm
- Triple-Negative Breast Neoplasms
- ER-Negative PR-Negative HER2-Negative Breast Cancer
- ER Negative PR Negative HER2 Negative Breast Cancer
- Triple Negative Breast Cancer
|
Below are MeSH descriptors whose meaning is more general than "Triple Negative Breast Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Triple Negative Breast Neoplasms".
This graph shows the total number of publications written about "Triple Negative Breast Neoplasms" by people in this website by year, and whether "Triple Negative Breast Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 2 | 1 | 3 |
| 2014 | 6 | 2 | 8 |
| 2015 | 6 | 0 | 6 |
| 2016 | 7 | 1 | 8 |
| 2017 | 6 | 0 | 6 |
| 2018 | 7 | 0 | 7 |
| 2019 | 11 | 0 | 11 |
| 2020 | 9 | 1 | 10 |
| 2021 | 13 | 0 | 13 |
| 2022 | 7 | 0 | 7 |
| 2023 | 9 | 0 | 9 |
| 2024 | 7 | 4 | 11 |
To return to the timeline,
click here.
Below are the most recent publications written about "Triple Negative Breast Neoplasms" by people in Profiles.
-
Case-Case Genome-Wide Analyses Identify Subtype-Informative Variants That Confer Risk for Breast Cancer. Cancer Res. 2024 Aug 01; 84(15):2533-2548.
-
PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers. Br J Cancer. 2024 Sep; 131(5):820-831.
-
Genome-wide association analyses of breast cancer in women of African ancestry identify new susceptibility loci and improve risk prediction. Nat Genet. 2024 May; 56(5):819-826.
-
Glucocorticoid receptor-mediated oncogenic activity is dependent on breast cancer subtype. J Steroid Biochem Mol Biol. 2024 Oct; 243:106518.
-
MerTK Drives Proliferation and Metastatic Potential in Triple-Negative Breast Cancer. Int J Mol Sci. 2024 May 08; 25(10).
-
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nat Commun. 2024 Mar 27; 15(1):2691.
-
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy. J Pathol. 2024 Jun; 263(2):190-202.
-
Nanoparticles Synergize Ferroptosis and Cuproptosis to Potentiate Cancer Immunotherapy. Adv Sci (Weinh). 2024 Jun; 11(23):e2310309.
-
The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC). Clin Breast Cancer. 2024 Jun; 24(4):263-270.
-
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 Mar 01; 10(3):362-371.